Metabolic Flux and Stable Isotope Tracing
Tracer Selection
| Question | Tracer | Position matters because |
|---|---|---|
| Is glucose oxidised or exported as lactate? | [U-¹³C]glucose | Uniform label reports the destination, not the route |
| Is glutamine oxidised or reductively carboxylated? | [1-¹³C]glutamine or [U-¹³C]glutamine | C1 loss reports oxidation; retention reports reductive carboxylation |
| Does pyruvate enter via PDH or PC? | [3-¹³C]pyruvate or [1-¹³C]pyruvate | Different carbons label different products |
| Is fatty acid oxidation active? | [U-¹³C]palmitate | Label dilution by endogenous pools is the issue |
| Is serine synthesised or imported? | [U-¹³C]glucose | Reports synthesis; imported serine is unlabelled |
| Is one-carbon flux going to nucleotides or methylation? | [3-¹³C]serine | C3 is the one-carbon carrier |
Important distinction. Position-specific tracers answer mechanism questions; uniformly labelled tracers answer destination questions. Using a uniform tracer for a mechanism claim is the most common design error in this literature, because several routes produce overlapping isotopologue patterns.
Part 1 — Reading Mitochondrial Patterns
| Observation | Interpretation | Confounder |
|---|---|---|
| Citrate m+2 from [U-¹³C]glucose | One turn of PDH plus one turn of the cycle | Pyruvate cycling dilutes label |
| Citrate m+3 or m+4 | Pyruvate carboxylation, or multiple turns | Pool heterogeneity |
| Glutamine-derived citrate m+5 in hypoxia | Reductive carboxylation | Compartment mixing in bulk extracts |
| Succinate and fumarate labelled asymmetrically | Cycle turnover with exchange | Reverse flux through SDH |
| Aspartate m+4 from [U-¹³C]glutamine | Glutamine anaplerosis to oxaloacetate | Transamination equilibrium |
| Malate m+3 from [1-¹³C]glucose | Pyruvate carboxylation | Shuttle exchange |
Readout note. Citrate is the most informative single metabolite in mitochondrial tracing, because it receives acetyl-CoA from several sources. Its isotopologue distribution reports which source dominated, provided the timepoint is short enough that recycling has not flattened the pattern.
Part 2 — From Labelling to Flux
| Requirement | What it means | Without it |
|---|---|---|
| Extracellular rates | Substrate consumption and product release | Only relative routing |
| A network model | Stoichiometry including compartmentation | No flux estimate |
| Steady-state assumption checked | Pools stable over the labelling window | Fluxes describe a transient |
| Isotopologue distribution, not one mass | Full mass isotopomer distribution | Conflation of routes |
| Identifiability assessment | Whether the data constrain the parameters | A curve fit presented as a flux |
| Fit quality reported | Residuals and confidence intervals | Precision without accuracy |
Caveat on "flux analysis" as a label. A paper that reports labelled fractions and calls the result "flux" has reported routing. Formal ¹³C metabolic flux analysis integrates the isotopologue data with extracellular rates and a defined network, and reports a fit. The distinction is not semantic: two routes can produce the same labelled fraction at different fluxes.
Part 3 — Design Choices That Determine the Answer
| Choice | Consequence |
|---|---|
| Labelling duration | Short: routing. Long: recycling and steady state |
| Tracer concentration | Must be saturating, or the flux depends on supply |
| Medium composition | Competing substrates change the partition |
| Cell density | Changes per-cell rates and oxygen availability |
| Sampling and quenching | Degradation and re-equilibration artefacts |
| Compartment inference | Bulk extracts average mitochondrial and cytosolic pools |
Important distinction. Tracer concentration is a design variable, not a detail. At subsaturating concentrations, the measured labelling reports the transporter and the medium, not the pathway capacity. Most protocols use saturating concentrations for this reason, but a "physiological concentration" experiment is a different design with a different interpretation.
Part 4 — What Tracing Can and Cannot Support
| Claim | Supported | Not supported |
|---|---|---|
| "Glucose carbon reached the TCA cycle" | Yes, from citrate labelling | The rate at which it did |
| "Reductive carboxylation occurred" | Yes, from citrate m+5 in hypoxia | Its quantitative contribution without a model |
| "Glutamine is the main anaplerotic substrate" | Provisionally | A fraction of total anaplerosis, without MFA |
| "Flux through PDH increased" | Only with MFA or a PDH-specific design | Labelled fraction alone |
| "The pathway is required" | No | Any labelling result |
Part 5 — A Worked Design
A concrete example: does a tumour line oxidise glutamine or use it for reductive carboxylation?
| Element | Choice | Reason |
|---|---|---|
| Tracer | [U-¹³C]glutamine, with a [1-¹³C]glutamine arm | C1 loss distinguishes oxidation from reductive use |
| Timepoints | 1, 4 and 12 hours | Routing at 1 h; recycling visible by 12 h |
| Substrate background | Glucose present, glutamine at the experimental concentration | Competing substrates change the partition |
| Oxygen | Normoxia and 1% O₂ arms | Reductive carboxylation is hypoxia-favoured |
| Readouts | Citrate, malate, aspartate, 2-HG, palmitate | Citrate for route; palmitate for lipogenic use |
| Extracellular rates | Glutamine consumption, ammonia, lactate | Needed for any absolute claim |
| Model | Compartmented network with IDH forward and reverse | Single pool cannot represent both directions |
The two-tracer design is what makes the claim specific: [U-¹³C]glutamine shows where carbon arrived, and [1-¹³C]glutamine shows whether the first carbon was lost as CO₂. Concordance between the two is the evidence; either alone is a pattern.
The palmitate readout deserves a note: lipogenesis from glutamine is the functional consequence of reductive carboxylation, and it is the readout that a reviewer will look for. It requires enough label incorporation to detect, which is why the 12-hour timepoint is included.
Part 6 — Common Failures
- • Uniform tracer used for a mechanism claim.
- • A single timepoint, so recycling cannot be assessed.
- • One mass isotopologue reported instead of the distribution.
- • Labelled fraction reported as flux.
- • Tracer concentration not stated, or subsaturating.
- • Extracellular rates not measured, precluding absolute flux.
- • Compartment inferred from bulk data.
- • Natural abundance not corrected.
- • MFA reported without an identifiability check.
Part 7 — Where This Article Connects
This is the tracing-principles article of the mitochondrial cluster. The analysis workflow article in this cluster covers the computational steps; the oncometabolite article covers the specific measurements for 2-HG and succinate; and the glucose pillar covers the general isotopologue interpretation that this article applies to mitochondrial questions.
If you need tracing designed around a specific mitochondrial route with extracellular rates and a fit assessment, we can scope the study with you.
Contact EDITGENE to request a project consultation or quote.
Scientific scope and validation note
Labelling patterns, pool sizes and route contributions vary with cell type, medium, oxygen tension and labelling duration. The interpretations here are conditional on the design.
An isotopologue pattern identifies routing; it does not establish an absolute flux without extracellular rates and a validated model.
Scientific interpretation and experimental design
- • Position-specific tracers answer mechanism. Uniform tracers answer destination.
- • Citrate reports the source. Keep the window short.
- • Flux needs rates and a model.
- • Check the steady state.
- • Report the distribution, not one mass.
- • Tracer concentration is a variable.
Selected references for further reading
- • Buescher JM, et al. A roadmap for interpreting ¹³C metabolite labeling patterns from cells. Current Opinion in Biotechnology. 2015;34:189–201.
- • Antoniewicz MR. A guide to ¹³C metabolic flux analysis for the cancer biologist. Experimental & Molecular Medicine. 2018;50:1–13.
- • Jang C, et al. Metabolomics and isotope tracing. Cell. 2018;173:822–837.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »